The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience

Pope Research

Status: Withdrawn

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT03109470

PRC-03-2012

Details and patient eligibility

About

Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require treatment with another biologic medication.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Completed 2 years in the FUNCTION (WA19926) trial
• Patient has provided written informed consent and is willing to comply with the requirements of this study protocol

Exclusion criteria

• Requirement for immediate treatment with a biologic therapy following completion of the FUNCTION (WA19926) trial as per treating physician judgement.
• Presence of any condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of RA